Patents by Inventor Judith Straub

Judith Straub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO
    Publication number: 20230183276
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: February 22, 2023
    Publication date: June 15, 2023
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Selective inhibitors of ERK protein kinase and uses thereof
    Patent number: 7501415
    Abstract: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 10, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Aronov, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Prodrugs of an ERK protein kinase inhibitor
    Patent number: 7358258
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: April 15, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Patent number: 7354939
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: April 8, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gabriel Martinez-Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7345054
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 18, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7304061
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: December 4, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • Heterocyclic protein kinase inhibitors and uses thereof
    Patent number: 7244735
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 17, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Judith Straub, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Alex Aronov, Guy Bemis
  • Selective inhibitors of ERK protein kinase and uses thereof
    Publication number: 20060160807
    Abstract: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Application
    Filed: December 20, 2005
    Publication date: July 20, 2006
    Inventors: Alexander Aronov, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Inhibitors of ERK protein kinase and uses thereof
    Publication number: 20060142572
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, Z1, Z2, U, Q, R1, R2, and L are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Application
    Filed: December 13, 2005
    Publication date: June 29, 2006
    Inventors: Gabriel Martinez-Botella, Alex Aronov, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Pyrazole compositions useful as inhibitors of erk
    Patent number: 7056944
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: June 6, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Publication number: 20060106069
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 13, 2005
    Publication date: May 18, 2006
    Inventors: Gabriel Martinez-Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Prodrugs of an ERK protein kinase inhibitor
    Publication number: 20060058318
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 13, 2005
    Publication date: March 16, 2006
    Inventors: Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Heterocyclic protein kinase inhibitors and uses thereof
    Publication number: 20050245499
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Application
    Filed: December 2, 2004
    Publication date: November 3, 2005
    Inventors: Judith Straub, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Alex Aronov, Guy Bemis
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20050234059
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Application
    Filed: March 10, 2005
    Publication date: October 20, 2005
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • Pyrazole compositions useful as inhibitors of ERK
    Publication number: 20040102506
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1
    Type: Application
    Filed: October 17, 2003
    Publication date: May 27, 2004
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6699865
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: March 2, 2004
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Patent number: RE46097
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: August 9, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
    Patent number: RE47318
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 26, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Patent number: RE48266
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: October 20, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Patent number: RE49500
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: April 25, 2023
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Gabriel Martinez Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang